Picoplatin
Picoplatin is an analog of cisplatin with a 2-methylpyridine ligand that displays anticancer chemotherapeutic activity. Picoplatin is used to treat non-small cell lung cancer (NSCLC) and is in clinical trials as a potential treatment for prostate cancer. Picoplatin intercalates with GpG sequences in DNA and shows efficacy inhibiting tumor growth in vitro, in vivo, and in clinical settings.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18954236
| Cas No. |
181630-15-9 |
|---|---|
| Purity |
≥98% |
| Formula |
C6H10Cl2N2Pt |
| Formula Wt. |
376.15 |
| Chemical Name |
azane; 2-methylpyridine; platinum(2+); dichloride |
| IUPAC Name |
azane;2-methylpyridine;platinum(2+);dichloride |
| Appearance |
White to pale yellow powder |
Matos CS, de Carvalho AL, Lopes RP, et al. New strategies against prostate cancer–Pt(II)-based chemotherapy. Curr Med Chem. 2012;19(27):4678-87. PMID: 22856665.
Eckardt JR, Bentsion DL, Lipatov ON, et al. Phase II study of picoplatin as second-line therapy for patients with small-cell lung cancer. J Clin Oncol. 2009 Apr 20;27(12):2046-51. PMID: 19289620.
Kanzawa F, Akiyama Y, Saijo N, et al. In vitro effects of combinations of cis-amminedichloro (2-methylpyridine) platinum (II) (ZD0473) with other novel anticancer drugs on the growth of SBC-3, a human small cell lung cancer cell line. Lung Cancer. 2003 Jun;40(3):325-32. PMID: 12781432.
Munk VP, Diakos CI, Ellis LT, et al. Investigations into the interactions between DNA and conformationally constrained pyridylamineplatinum(II) analogues of AMD473. Inorg Chem. 2003 Jun 2;42(11):3582-90. PMID: 12767196.
